Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis PharmaceuticalsMIL:1IONS 48 Days Payable is 1,226.45 as of Jun. 2026, which is 45% above its 10-year median of 846.60. GuruFocus rates MIL:1IONS with a GF Score™ of 48/100 and a GF Value™ of €44.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Ionis Pharmaceuticals ranks better than 82.08% on this metric.
Ionis Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1IONS vs KYMR, PRAX, HALO: Days Payable Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ionis Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (MIL:1IONS) has a Days Payable of 1,226.45 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ionis Pharmaceuticals and its competitors. This is 45% above median its historical median of 846.60. Over the past decade, Ionis Pharmaceuticals' Days Payable has ranged from 385.60 to 5,369.31. According to the industry distribution chart, Ionis Pharmaceuticals ranks #126 out of 703 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Ionis Pharmaceuticals' Days Payable too high?
Ionis Pharmaceuticals' current Days Payable of 1,226.45 is 45% above median its 10-year median of 846.60. Over the past 10 years, this metric has ranged from a low of 385.60 to a high of 5,369.31. The Biotechnology industry median Days Payable is 112.84. Ionis Pharmaceuticals' value of 1,226.45 is 986.9% above this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #126 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ionis Pharmaceuticals has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Days Payable compare to KYMR and PRAX?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #126 out of 703 companies for Days Payable. This places Ionis Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Ionis Pharmaceuticals' value of 1,226.45 is 986.9% above this benchmark. Historically, Ionis Pharmaceuticals' own Days Payable has ranged from 385.60 to 5,369.31 over the past decade. While the company's 10-year median is 846.60 vs. the industry median of 112.84, Ionis Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Days Payable of 1,226.45 is 986.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Days Payable is 1,226.45, which is 45% above median its own 10-year median of 846.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MIL:1IONS) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.73, compared to a current price of €48.44 — trading 8.3% above its estimated fair value. The current Days Payable is 1,226.45, which is 45% above median its 10-year median of 846.60 and 986.9% above the Biotechnology industry median of 112.84. Ionis Pharmaceuticals' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ionis Pharmaceuticals (MIL:1IONS), the current Days Payable is 1,226.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MIL:1IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of €48.44 is trading 8.3% above its estimated GF Value™ of €44.73.
GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for MIL:1IONS:
Days Payable: 1,226.45 (45% above median its 10-year median of 846.60)
GF Value™: €44.73 vs. price of €48.44 (8.3% above fair value)
Industry Position: 986.9% above the Biotechnology median (#126 of 703)
No single metric tells the full story. See the MIL:1IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
48GF Score
Get the complete analysis for MIL:1IONS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1IONS has been successfully added to your 
